Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survodutide Once Weekly for the Treatment of Adults with Obesity.

The New England journal of medicine·2026
Same author

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.

Obesity (Silver Spring, Md.)·2026
Same author

Correction: Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.

International journal of obesity (2005)·2025
Same author

Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.

International journal of obesity (2005)·2025
Same author

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.

Obesity (Silver Spring, Md.)·2025
Same journal

Life's essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.

Expert review of cardiovascular therapy·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
Same journal

Contemporary approach and key considerations to asymptomatic aortic stenosis treatment.

Expert review of cardiovascular therapy·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe: cholesterol lowering and beyond.

Harold E Bays1, David Neff, Joanne E Tomassini

  • 1Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. hbaysmd@aol.com

Expert Review of Cardiovascular Therapy
|April 12, 2008
PubMed
Summary
This summary is machine-generated.

Ezetimibe inhibits cholesterol absorption by blocking intestinal sterol transporters. This lowers LDL-cholesterol and may reduce cardiovascular risk when used alone or with statins.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Ezetimibe is a cholesterol absorption inhibitor.
  • It targets intestinal sterol transporters, specifically Niemann-Pick C1-like 1 proteins.

Purpose of the Study:

  • To describe the mechanism of action and lipid-lowering effects of ezetimibe.
  • To outline its role in managing dyslipidemia and cardiovascular risk.

Main Methods:

  • Inhibition of cholesterol absorption via sterol transporter blockade.
  • Monotherapy and combination therapy with statins.

Main Results:

  • Ezetimibe lowers LDL-cholesterol, non-HDL-cholesterol, and apolipoprotein B.
  • It may increase HDL-cholesterol and decrease triglycerides.
  • Combination therapy with statins can reduce high-sensitivity C-reactive protein.

Conclusions:

  • Ezetimibe effectively reduces LDL-cholesterol and offers potential cardiovascular benefits.
  • Its clinical significance in outcome studies is under ongoing evaluation.